MDL 100240

Drug Profile

MDL 100240

Alternative Names: 100240; M 100240; MDL100240

Latest Information Update: 17 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Benzazepines; Carboxylic acids; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-II for Congestive heart failure in Europe (PO)
  • 11 Feb 2009 Discontinued - Phase-II for Congestive heart failure in USA (PO)
  • 09 Feb 2005 A clinical study has been added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top